TY - JOUR
T1 - Therapeutic advantage of angiotensin converting enzyme inhibitors in chronic glomerulonephritis
AU - Omata, Ken
AU - Saito, Takao
AU - Sato, Hiroshi
AU - Sato, Tatsuyuki
AU - Abe, Fumiaki
AU - Yamada, Masaaki
AU - Yaoita, Hiraku
AU - Endo, Yoshimi
AU - Ito, Sadayoshi
AU - Kanazawa, Msayuki
AU - Abe, Keishi
N1 - Funding Information:
We are indebted to the patients who participated in the Study of The Recommendation of Antihypertensive Therapy: Blood Pressure Level and Antihypertensive Agents, The Research Group of Progressive Renal Lesions. This study was supported by Grants-in-Aid (No. 07457237 and No. 05454338) for Scientific Research from the Ministry of Education, Science and Culture, Japan, by a research Grant (Progressive Renal Lesions) from the Intractable Disease Division, Public Health Bureau, the Ministry of Health and Welfare, Japan and by a Research Grant from the Miyagi Prefecture Kidney Association, Japan. The following institutions and investigators participated in the study of The Recommendation of Antihypertensive Therapy: Blood Pressure Level and Antihypertensive Agents, The Research Group of Progressive Renal Lesions: Tohoku University School of Medicine — T. Ohtaka, J. Soma, A. Yusa; National Cardiovascular Center — G. Kimura; Faculty of Medicine, Kyusyu University — S. Okuda; School of Medicine, Keio University — H. Suzuki; Sakura National Hospital — K. Yamada; Toride Kyodo Hospital — T. Shiigai.
Funding Information:
We designed the study to clarify the adequate blood pressure level and to compare the effect of ACE inhibitors and calcium antagonists in patients with chronic glomerulonephritis. A prospective, multi-center randomized trial was planned by The Research Group of the Progressive Renal Lesions, the Intractable Disease Division (Director Kiyoshi Kurokawa, Faculty of Medicine, University of Tokyo) supported by Public Health Bureau of the Ministry of Health and Welfare, Japan.
PY - 1999/10/15
Y1 - 1999/10/15
N2 - Hypertension in chronic progressive renal disease is a major clinical problem leading to renal function loss. We studied the influence of ambulatory blood pressure (ABP) and the effect of hypertension therapy on renal function in 116 patients with chronic glomerulonephritis. Patients were subdivided as hypertensive, normotensive and hypotensive according to the level of ABP and age. Hypotensive subjects showed improvement of renal function and normotensive subjects showed slower rate of progression of renal function loss than hypertensives, suggesting the adequate level of ABP was 100-125/55-75 mm Hg in patients less than 40 years old, 100-135/60-80 mm Hg in patients 40-60 years old, and 105-140/60-85 mm Hg in patients over 60 years, respectively. The renal protection of calcium antagonists was associated with achieving lower blood pressure levels, whereas the blood pressure level did not affect progression of renal function in patient treated with angiotensin converting enzyme (ACE) inhibitor. ACE inhibitor, but not calcium antagonists, showed a reduction of urinary protein excretion. Thus, the mechanisms of renal protection were different between ACE inhibitors and calcium antagonists. Copyright (C) 1999 Elsevier Science B.V.
AB - Hypertension in chronic progressive renal disease is a major clinical problem leading to renal function loss. We studied the influence of ambulatory blood pressure (ABP) and the effect of hypertension therapy on renal function in 116 patients with chronic glomerulonephritis. Patients were subdivided as hypertensive, normotensive and hypotensive according to the level of ABP and age. Hypotensive subjects showed improvement of renal function and normotensive subjects showed slower rate of progression of renal function loss than hypertensives, suggesting the adequate level of ABP was 100-125/55-75 mm Hg in patients less than 40 years old, 100-135/60-80 mm Hg in patients 40-60 years old, and 105-140/60-85 mm Hg in patients over 60 years, respectively. The renal protection of calcium antagonists was associated with achieving lower blood pressure levels, whereas the blood pressure level did not affect progression of renal function in patient treated with angiotensin converting enzyme (ACE) inhibitor. ACE inhibitor, but not calcium antagonists, showed a reduction of urinary protein excretion. Thus, the mechanisms of renal protection were different between ACE inhibitors and calcium antagonists. Copyright (C) 1999 Elsevier Science B.V.
KW - Angiotensin converting enzyme (ACE) inhibitor
KW - Calcium antagonist
KW - Chronic renal disease
UR - http://www.scopus.com/inward/record.url?scp=0032734607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032734607&partnerID=8YFLogxK
U2 - 10.1016/S0162-3109(99)00141-1
DO - 10.1016/S0162-3109(99)00141-1
M3 - Article
C2 - 10604523
AN - SCOPUS:0032734607
SN - 0162-3109
VL - 44
SP - 43
EP - 48
JO - Immunopharmacology
JF - Immunopharmacology
IS - 1-2
ER -